Off-label drugs in palliative care: a Group Delphi treatment recommendation process
C Remi, K Weingärtner, V Hagemann… - BMJ Supportive & …, 2021 - spcare.bmj.com
Objectives The use of drugs beyond their marketing authorisation, that is, off-label use, is
common practice in palliative care with over 70% of off-label use having little or no scientific …
common practice in palliative care with over 70% of off-label use having little or no scientific …
Off-label drugs in palliative care: a Group Delphi treatment recommendation process
C Remi, K Weingärtner… - BMJ supportive & …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives The use of drugs beyond their marketing authorisation, that is, off-label use, is
common practice in palliative care with over 70% of off-label use having little or no scientific …
common practice in palliative care with over 70% of off-label use having little or no scientific …
Off-label drugs in palliative care: a Group Delphi treatment recommendation process
C Remi, K Weingärtner, V Hagemann… - BMJ Supportive & …, 2020 - spcare.bmj.com
Objectives The use of drugs beyond their marketing authorisation, that is, off-label use, is
common practice in palliative care with over 70% of off-label use having little or no scientific …
common practice in palliative care with over 70% of off-label use having little or no scientific …
Off-label drugs in palliative care: a Group Delphi treatment recommendation process
C Remi, K Weingärtner, V Hagemann… - BMJ Supportive & …, 2021 - search.proquest.com
Objectives The use of drugs beyond their marketing authorisation, that is, off-label use, is
common practice in palliative care with over 70% of off-label use having little or no scientific …
common practice in palliative care with over 70% of off-label use having little or no scientific …
Off-label drugs in palliative care: a Group Delphi treatment recommendation process.
C Remi, K Weingärtner, V Hagemann… - BMJ Supportive & …, 2020 - europepmc.org
Objectives The use of drugs beyond their marketing authorisation, that is, off-label use, is
common practice in palliative care with over 70% of off-label use having little or no scientific …
common practice in palliative care with over 70% of off-label use having little or no scientific …
Off-label drugs in palliative care: a Group Delphi treatment recommendation process
C Remi, K Weingaertner… - BMJ Supportive & …, 2021 - epub.ub.uni-muenchen.de
Objectives The use of drugs beyond their marketing authorisation, that is, off-label use, is
common practice in palliative care with over 70% of off-label use having little or no scientific …
common practice in palliative care with over 70% of off-label use having little or no scientific …